Gain Therapeutics, Inc. (NASDAQ:GANX) Director Acquires $20,740.00 in Stock

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Eric I. Richman purchased 17,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were acquired at an average price of $1.22 per share, for a total transaction of $20,740.00. Following the completion of the transaction, the director now owns 289,629 shares in the company, valued at $353,347.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Gain Therapeutics Trading Down 12.5 %

Shares of Gain Therapeutics stock traded down $0.16 during trading on Monday, reaching $1.12. 612,586 shares of the company were exchanged, compared to its average volume of 204,152. Gain Therapeutics, Inc. has a twelve month low of $1.11 and a twelve month high of $5.33. The business has a 50-day moving average price of $2.32 and a 200-day moving average price of $3.29. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $20.22 million, a price-to-earnings ratio of -0.76 and a beta of 0.35.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Sell-side analysts anticipate that Gain Therapeutics, Inc. will post -1.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GANX. Chardan Capital restated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research report on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, May 28th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.